Tissue Regenix Group PLC TRX BioSurgery GPO agreement with Premier, Inc. (8203M)
02 May 2018 - 4:00PM
UK Regulatory
TIDMTRX
RNS Number : 8203M
Tissue Regenix Group PLC
02 May 2018
TRX BioSurgery extends GPO agreement with Premier, Inc.
Under a 3 year Tissue, Implantable Products contract DermaPure
maintains access to c. 3,900 U.S. hospitals and
> 150,000 provider organisations
Leeds, 2 May 2018 - Tissue Regenix Group (AIM:TRX) ("Tissue
Regenix" or "The Group") the regenerative medical devices company,
today announced subsidiary TRX BioSurgery has been awarded a group
purchasing contract for DermaPure under a Tissue, Implantable
Products contract with Premier Inc., a leading healthcare
improvement company, effective for three years commencing 1 July,
2018.
Since the initial approval under Premier's 'Breakthrough
Technology Agreement' in December 2016, DermaPure has gained
clinical support throughout Premier's member institutions. Under
this new agreement Tissue Regenix salesforce maintains commercial
access to Premier's alliance of approximately 3,900 U.S. hospitals
and more than 150,000 care providers.
DermaPure has demonstrated clinical and health economic
advantages for inpatient applications. The product has been
increasingly deployed in a number of clinical areas including acute
and chronic wound care, orthopaedic trauma, dental, and following
the exclusive distribution agreement with ARMS medical,
urogynaecology and urology.
Joel Pickering, President TRX BioSurgery, commented: "We are
thrilled to extend our relationship with Premier, Inc. and to
continue to make DermaPure accessible to its member institutions.
The award of this new agreement highlights the need for novel
products such as DermaPure in a growing number of clinical areas.
We strive to achieve superior clinical outcomes and contribute to
improved health economics for both patients and health care
providers alike. Now with the capacity to manufacture product
inhouse at our CellRight facility and with growing advocacy of
DermaPure throughout the clinical community, the addition of this
agreement will enable us to continue to meet their clinical needs
now and in the future."
For more Information:
Tissue Regenix Group plc Tel: 0330 430 3073
Caitlin Pearson, Head of Communications / 07920272 441
----------------------------------------- -------------------
Jefferies International Ltd Tel: 020 7029 8000
Simon Hardy / Christopher Binks
----------------------------------------- -------------------
FTI Consulting Tel: 0203 727 1000
Brett Pollard / Mo Noonan/ Mary
Whittow
========================================= ===================
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. Tissue Regenix was formed in 2006 when it
was spun-out from the University of Leeds, UK. The company's
patented decellularisation ('dCELL(R) ') technology removes DNA and
other cellular material from animal and human soft tissue leaving
an acellular tissue scaffold which is not rejected by the patient's
body and can then be used to repair diseased or worn out body
parts. Current applications address many critical clinical needs
such as sports medicine, heart valve replacement and wound
care.
In November 2012 Tissue Regenix Group plc set up a subsidiary
company in the United States - 'Tissue Regenix Wound Care Inc.',
January 2016 saw the establishment of joint venture GBM-V, a multi-
tissue bank based in Rostock, Germany.
In August 2017 Tissue Regenix acquired CellRight Technologies(R)
, a biotech company that specializes in regenerative medicine and
is dedicated to the development of innovative osteoinductive and
wound care scaffolds that enhance healing opportunities of defects
created by trauma and disease. CellRight's human osteobiologics may
be used in spine, trauma, general orthopedic, foot & ankle,
dental, and sports medicine surgical procedures.
About Premier Inc.
Premier Inc. (NASDAQ: PINC) is a healthcare improvement company
uniting an alliance of approximately 3,900 U.S. hospitals and more
than 150,000 other provider organizations. Our mission is simple:
To improve the health of communities.
As an industry leader, Premier has created one of the most
comprehensive databases of actionable data, clinical best practices
and efficiency improvement strategies.
Our award-winning and revolutionary technologies enable our
members to collaborate more easily and efficiently. Our goal is to
improve our members' quality outcomes, while safely reducing costs.
By engaging members and revealing new opportunities, we empower the
alliance to improve the performance of healthcare
organizations.
Named one of the World's Most Ethical Companies 10 years in a
row, we are well-equipped to transform the future of
healthcare.
Please visit Premier's news and investor sites on
www.premierinc.com; as well as Twitter, Facebook, LinkedIn,
YouTube, Instagram, Foursquare and Premier's blog for more
information about the company.
This information is provided by RNS
The company news service from the London Stock Exchange
END
CNTMMGGKMMKGRZZ
(END) Dow Jones Newswires
May 02, 2018 02:00 ET (06:00 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Apr 2024 to May 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From May 2023 to May 2024